This online microburst enduring education aims to improve HCPs’ knowledge of the rationale and evidence for the use of TROP2-directed antibody drug conjugates (ADCs) in pretreated HR-positive, HER2-negative/low advanced breast cancer, as well as improve HCPs clinical skills related to the appropriate integration of such therapies.As a result of this educational activity, learners should be better able to: 1. Recognize the rationale for using TROP2-directed ADCs in the treatment of HR-positive, HER2-negative/low advanced breast cancer; 2. Discuss the clinical impact of approved and late-stage emerging TROP2-directed ADCs for patients with pretreated HR-positive, HER2-negative/low advanced breast cancer; and, 3. Outline guideline-concordant, evidence-based strategies to appropriately incorporate TROP2-directed ADCs into treatment plans for patients with pretreated HR-positive, HER2-negative/low advanced breast cancer. Downloadable slides and podcast are available to enhance learners’ clinical practice.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/EYY
- Start Date: 2024-12-19 06:00:00
- End Date: 2024-12-19 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 78000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 80000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all